Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects

Am Rev Respir Dis. 1987 Feb;135(2):333-7. doi: 10.1164/arrd.1987.135.2.333.


The bronchoconstrictor activity of an aerosol of leukotriene E4(LTE4) was compared with that of histamine in 5 normal and in 6 asthmatic subjects to define the relative potency of LTE4 between the groups using 3 indices of airway response. The FEV1 and the flow rate measured at 30% of vital capacity from partial and maximal expiratory maneuvers (V30-P and V30-M) were measured. The geometric mean (GSEM) concentration of LTE4 required to reduce the V30-P by 30% was 0.30 (1.46) mM in the normal subjects, and 0.058 (1.63) in the asthmatic subjects; LTE4 was 39-fold more potent than histamine in the former and 14-fold in the latter group. Further, we observed that when normal and asthmatic subjects were compared at a degree of bronchoconstriction resulting in a 30% decrement in the V30-P after inhaling LTE4, there was a greater response in the asthmatic group than in the normal group of the accompanying change in the FEV1. The decrements in the FEV1 were not significantly different between the 2 groups after inhaling histamine. This study demonstrates that LTE4 is a potent bronchoconstrictor agonist in humans and suggests that airway responsiveness to this agonist differs substantially with the index of bronchoconstriction used for assessment of airway response.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aerosols
  • Asthma / physiopathology*
  • Bronchial Spasm / chemically induced*
  • Bronchial Spasm / physiopathology
  • Dose-Response Relationship, Drug
  • Female
  • Forced Expiratory Volume
  • Histamine / pharmacology
  • Humans
  • Leukotriene E4
  • Male
  • Maximal Expiratory Flow Rate
  • Osmolar Concentration
  • SRS-A / analogs & derivatives*
  • SRS-A / pharmacology
  • Time Factors
  • Vital Capacity


  • Aerosols
  • SRS-A
  • Leukotriene E4
  • Histamine